Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Medicine, Aarhus University, Aarhus, Denmark.
Eur J Endocrinol. 2022 Feb 22;186(4):429-440. doi: 10.1530/EJE-21-0846.
Prenatal exposure to excess cortisol can affect postnatal metabolic health by epigenetic mechanisms. We aimed to investigate if prenatal exposure to pharmacological glucocorticoids increases the risk of overweight/obesity in childhood.
A nationwide population registry-based cohort study.
We identified 383 877 children born in Denmark (2007-2012), who underwent routine anthropometric evaluation at 5-8 years of age. Prenatal exposure to glucocorticoids was divided into systemic and topical glucocorticoids, cumulative systemic dose, and use by trimester. The comparison cohort included children without exposure, born to maternal never-users. Negative control exposures were used to investigate confounding from an underlying disease or unmeasured characteristics. Such exposures included children without glucocorticoid exposure born to maternal users of non-steroidal anti-inflammatory drugs or immunotherapy during pregnancy, maternal former users of glucocorticoids, or paternal users of glucocorticoids during the pregnancy of their partner. We estimated sex-stratified adjusted prevalence ratios (aPR) of overweight/obesity at 5-8 years of age, as epigenetic modifications have shown to be sex-specific.
In the study, 21 246 (11%) boys and 27 851 (15%) girls were overweight/obese at 5-8 years of age. Overall, neither systemic nor topical glucocorticoids were associated with overweight/obesity. In boys, high-dose systemic glucocorticoids was associated with higher prevalence of overweight/obesity vs the comparison cohort (aPR: 1.41 (95% CI: 1.07-1.86), prevalence: 16% vs 11%). Negative control exposures indicated robustness to confounding.
Overweight/obesity might be an adverse effect of prenatal exposure to high-dose systemic glucocorticoids in boys. We found no association for neither prenatal exposure to lower doses of systemic nor topical glucocorticoids. These results merit clinical attention.
产前暴露于过量皮质醇可通过表观遗传机制影响产后代谢健康。我们旨在研究产前暴露于药理学皮质激素是否会增加儿童超重/肥胖的风险。
一项基于全国人口登记的队列研究。
我们确定了 383877 名在丹麦出生的儿童(2007-2012 年),他们在 5-8 岁时接受了常规人体测量评估。皮质激素的产前暴露分为全身和局部皮质激素、累积全身剂量以及每个孕期的使用情况。对照组包括未暴露于皮质激素的儿童,他们的母亲在怀孕期间从未使用过皮质激素。阴性对照暴露用于调查潜在疾病或未测量特征引起的混杂。此类暴露包括在怀孕期间母亲使用非甾体抗炎药或免疫疗法的儿童,母亲以前使用过皮质激素,或父亲在其伴侣怀孕期间使用过皮质激素的儿童。我们估计了 5-8 岁时超重/肥胖的性别分层调整后患病率比(aPR),因为表观遗传修饰已被证明具有性别特异性。
在该研究中,21246 名(11%)男孩和 27851 名(15%)女孩在 5-8 岁时超重/肥胖。总体而言,全身和局部皮质激素均与超重/肥胖无关。在男孩中,高剂量全身皮质激素与超重/肥胖的患病率较高相关(aPR:1.41(95%CI:1.07-1.86),患病率:16%比 11%)。阴性对照暴露表明对混杂有稳健性。
男孩产前暴露于高剂量全身皮质激素可能会导致超重/肥胖。我们未发现产前暴露于较低剂量全身或局部皮质激素与超重/肥胖有关。这些结果值得临床关注。